Condition: Prostate Cancer · Sponsor: Henry Ford Health System
This is a pilot study to improve rates of germline genetic testing for black patients with aggressive prostate cancer as recommended by the updated guidelines by the National Cancer Comprehensive Network (NCCN) in 2018. In this study, consented patients will undergo a low-risk intervention of an educational session with a trained staff member on germline testing in prostate cancer and, if agreeable, subsequent germline cancer genetic testing via a commercial lab test.
This description comes directly from the study's public registry record.
Clara Hwang, MD · 313-556-8830 · chwang2@hfhs.org
Karthik Subramanian, MS · 313-401-9815 · ksubram3@hfhs.org
Always discuss trial participation with your own doctor first.
| Henry Ford Cancer Pavilion | Detroit, Michigan, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05958082